Sarepta Therapeutics Inc. (SRPT)

93.61
NASDAQ : Health Technology
Prev Close 95.07
Day Low/High 92.98 / 96.49
52 Wk Low/High 90.24 / 165.87
Avg Volume 1.45M
Exchange NASDAQ
Shares Outstanding 74.34M
Market Cap 7.07B
EPS -5.50
Div & Yield N.A. (N.A)

Latest News

SRPT: Insiders Vs. Shorts

SRPT: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Sarepta Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 10.58 "days to cover" versus the median component at 5.30. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.

Sarepta Therapeutics To Announce Second Quarter 2019 Financial Results And Recent Corporate Developments On August 7, 2019

Sarepta Therapeutics To Announce Second Quarter 2019 Financial Results And Recent Corporate Developments On August 7, 2019

CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.

Sarepta Therapeutics Looks Ready to Break Out to the Upside

Sarepta Therapeutics Looks Ready to Break Out to the Upside

Here's how to play this stock.

WATCH for Scale: Cramer's 'Mad Money' Recap (Thursday 7/11/19)

WATCH for Scale: Cramer's 'Mad Money' Recap (Thursday 7/11/19)

Jim Cramer highlights companies that can grow so big they make their own destinies: Walmart, Amazon, Target, Costco and Home Depot.

Sarepta Therapeutics Soars as Pfizer's Competing Drug Shows Safety Problems

Sarepta Therapeutics Soars as Pfizer's Competing Drug Shows Safety Problems

An analyst at Baird says a Pfizer gene therapy drug had safety and efficacy issues during a study.

Chart of the Week: Sarepta Therapeutics

SRPT is pushing to break free.

Hopeful Signs for These 2 Small Biotech Stocks

Hopeful Signs for These 2 Small Biotech Stocks

Few parts of this biotech space are more frustrating that what I have dubbed 'Tier 3' biotech concerns.

Noteworthy Wednesday Option Activity: SRPT, PII, BREW

Noteworthy Wednesday Option Activity: SRPT, PII, BREW

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Sarepta Therapeutics Inc , where a total volume of 5,405 contracts has been traded thus far today, a contract volume which is representative of approximately 540,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 51.5% of SRPT's average daily trading volume over the past month, of 1.0 million shares.

DexCom, HCA Healthcare, Tractor Supply: 'Mad Money' Lightning Round

DexCom, HCA Healthcare, Tractor Supply: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at DexCom, HCA Healthcare, Tractor Supply, Sarepta Therapeutics, The Blackstone Group, HNI Corp. and more.

Investing's Not a Game: Cramer's 'Mad Money' Recap (Thursday 4/25/19)

Investing's Not a Game: Cramer's 'Mad Money' Recap (Thursday 4/25/19)

Jim Cramer says it's the start CNBC's annual Stock Draft Contest, but he cautions Mad Money viewers that although investing can be fun, it requires discipline and doing your homework.

Is This Market Action Foreshadowing Something Worse?

Is This Market Action Foreshadowing Something Worse?

This trading is starting to create some fairly deep pullbacks.

Sarepta Therapeutics' Charts Look Risky

Sarepta Therapeutics' Charts Look Risky

In a red flag for investors, the charts show sellers are getting more aggressive with Sarepta.

Bank of America, YY, Okta: 'Mad Money' Lightning Round

Bank of America, YY, Okta: 'Mad Money' Lightning Round

Jim Cramer weighs in on Bank of America, YY, Okta, Sarepta Therapeutics, Wendy's, ADT, New Residential Investment, First Interstate Bancshares and more.

The Perils of Stock Investing: Cramer's 'Mad Money' Recap (Thursday 3/14/19)

The Perils of Stock Investing: Cramer's 'Mad Money' Recap (Thursday 3/14/19)

On the 14th anniversary for 'Mad Money', Jim Cramer talks about how to balance owning index funds and individual stocks.

You've Got to Ask Yourself One Question: 'Do I Feel Lucky?'

You've Got to Ask Yourself One Question: 'Do I Feel Lucky?'

Luck is our constant companion in the stock market and we are fools if we ignore that fact.

The Bears Now Have Possession of the Ball After Bulls Fumble It Away

The Bears Now Have Possession of the Ball After Bulls Fumble It Away

Can they finally put some points on the board?

Sarepta Shares Surge on Positive Muscular Dystrophy Trial, Myonexus Acquisition

Sarepta Shares Surge on Positive Muscular Dystrophy Trial, Myonexus Acquisition

Shares of Sarepta Therapeutics surge after the company announces an early stage study of a gene-therapy treatment that could benefit patients with a rare form of muscular dystrophy shows promising results.

Win, With or Without China: Cramer's 'Mad Money' Recap (Monday 2/25/19)

Win, With or Without China: Cramer's 'Mad Money' Recap (Monday 2/25/19)

Jim Cramer asks whether there aren't enough good things happening that we can sustain an advance without a China deal.

Cisco Systems, Deutsche Bank, CVS: 'Mad Money' Lightning Round

Cisco Systems, Deutsche Bank, CVS: 'Mad Money' Lightning Round

Jim Cramer takes a look at Cisco Systems, Deutsche Bank, CVS, Trimble Navigation, Sarepta Therapeutics, Foot Locker, Nike and more.

Chart of the Day: Sarepta Therapeutics

If this stock breaks through resistance, we could see a powerful run towards the $200 area.

Notable Thursday Option Activity: SRPT, LCI, OFIX

Notable Thursday Option Activity: SRPT, LCI, OFIX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Sarepta Therapeutics Inc , where a total volume of 4,094 contracts has been traded thus far today, a contract volume which is representative of approximately 409,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 43.7% of SRPT's average daily trading volume over the past month, of 937,745 shares.

Fear of Missing Out Is the Main Driving Force in This Market

Fear of Missing Out Is the Main Driving Force in This Market

Stick to your methodology and don't let worry of underperformance push you to shift your approach.

The Market Is Transitioning Back to Stock Picking

The Market Is Transitioning Back to Stock Picking

There are obvious signs that people are trying to put cash to work.

Quiet Trading Allowing Some Biotech Names to Perk Up

Quiet Trading Allowing Some Biotech Names to Perk Up

After two chaotic days, Wall Street is trading relatively calmly, creating opportunities for individual names to show life.

TheStreet Quant Rating: D (Sell)